Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.50    1.50 (2.14%)
Bid:
71.00
Ask:
72.00
Spread: 1.00 (1.408%)
Market Cap: £325.40m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Re Agreement

3 Sep 2007 07:00

Avacta Group plc

Development Contract with the MOD's Defence science and technology laboratory

Field Detection of Liquid Chemicals

Avacta Group plc ("Avacta"), which develops detection and analysis technology aimed at the defence & security, pharmaceutical and clinical diagnostics markets, announces a contract with the Defence science and technology laboratory (Dstl), which is part of the UK Ministry of Defence.

Avacta is developing methods of analysing liquids using laser spectroscopy. The goal is to enable the rapid detection of liquids in the field.

Professor Alastair Smith, Chief Executive, Avacta, commented:

"We are delighted with the new contract for the development of a robust, prototype device. Laser detection and diagnostic devices are a key part of Avacta's portfolio of technologies and this contract with the MOD is an important step for the company."

3 September 2007Enquiries:Avacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk W.H. Ireland Ltd Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Ltd Tel: 020 7099 1942 Michael Brennan/Henry Turcan Notes to Editors:About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in defence and clinical diagnostics are also being provided by Avacta's development programmes. A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Ltd which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed on AIM in August 2006 through the reverse takeover of Readybuy plc which changed its name to Avacta Group plc.

AVACTA GROUP PLC
Date   Source Headline
17th Oct 20137:00 amRNSFirst therapeutic licensing agreement for Affimers
26th Sep 20137:00 amRNSLaunch of Sensipod - First Point of Care Test
18th Sep 20137:00 amRNSIssue of Equity and Notice of Preliminary Results
16th Sep 20137:00 amRNSNew Head of R&D Joins Avacta
2nd Sep 20135:47 pmRNSTR-1 Notification of Major Interest in Shares
29th Aug 20137:00 amRNSPre-close trading update
28th Aug 20137:00 amRNSIssue of Equity
9th Aug 20138:35 amRNSTR-1: Notification of Major Interest in Shares
7th Aug 20135:51 pmRNSTR-1: Notification of Major Interest in Shares
7th Aug 20134:31 pmRNSTR-1: Notification of Major Interest in Shares
7th Aug 20134:30 pmRNSTR-1: Notification of Major Interest in Shares
7th Aug 20134:00 pmRNSTR-1: Notification of Major Interest in Shares
5th Aug 201311:00 amRNSResult of General Meeting
5th Aug 20137:00 amRNSAppointment of a Non-Executive Director
25th Jul 20137:00 amRNSExpansion of Collaboration with ForteBio
18th Jul 20137:00 amRNSConditional Placing to Raise £4.7 Million
23rd May 20138:40 amRNSHolding(s) in Company
30th Apr 20137:00 amRNSInterim Results
23rd Apr 20137:01 amRNSNotice of Interim Results
23rd Apr 20137:00 amRNSAppointment of Nominated Advisor and Broker
27th Feb 20137:00 amRNSInterest in Affimer Technology
27th Feb 20137:00 amRNSBusiness Update
18th Feb 20135:08 pmRNSAdditional Listing
25th Jan 20132:34 pmRNSResult of AGM
21st Jan 20131:20 pmRNSHolding(s) in Company
7th Jan 20133:47 pmRNSHolding(s) in Company
23rd Oct 20127:00 amRNSPreliminary Results
24th Sep 20127:00 amRNSAvacta and Pall extend Optim distribution to India
13th Sep 201210:24 amRNSNotice of Preliminary Results
24th Aug 20127:00 amRNSPre-close trading update
19th Jun 20125:05 pmRNSHolding(s) in Company
25th Apr 20127:00 amRNSInterim Results
2nd Apr 20127:00 amRNSAvacta Signs Exclusive Supply Deal with IDEXX
15th Mar 20127:00 amRNSNotice of Interim Results
24th Jan 201210:39 amRNSResult of AGM
19th Jan 20126:23 pmRNSHolding(s) in Company
12th Jan 201211:12 amRNSHolding(s) in Company
10th Jan 20129:26 amRNSCompletes £5.13m placing and Aptuscan acquisition
9th Jan 20124:10 pmRNSResults of General Meeting
22nd Dec 20117:00 amRNSConditional Placing and Proposed Acquisition
8th Dec 20112:20 pmRNSNotice of AGM and Report and Accounts
25th Nov 20117:00 amRNSAdditional Listing & Total Voting Rights
25th Oct 20117:00 amRNSPreliminary Results
21st Oct 20117:00 amRNSAppointment of Nomad and Broker
5th Oct 20117:00 amRNSSouth East Asian Alliance agreed with Pall
19th Sep 20117:00 amRNSNotice of Preliminary Results
9th Aug 20117:00 amRNSPre-close Trading Update
6th Jul 20117:00 amRNSChange of Registered Office
10th Jun 201112:50 pmRNSDirector/PDMR Shareholding
31st May 20117:00 amRNSAvacta secures second Optim sale in US

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.